SCHEMBL24257581

SCHEMBL24257581

Cc1c(-c2cnn(C(C)C)c2)cnc(C#N)c1OCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 2/20 0.38
KDM5A P29375 1/20 0.36
PDK2 Q15119 2/20 0.34
ATP4A P20648 1/20 0.34
ATP4B P51164 1/20 0.34
GRM4 Q14833 1/20 0.34
SQOR Q9Y6N5 1/20 0.34
MAPT P10636 2/20 0.34
HSD17B10 Q99714 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257579 0.86 RET (0.40) RETKDM5APDK2ATP4AATP4B
SCHEMBL24257678 0.84 GRM4 (0.50) KDM5AGRM4MAPTKDM4EALDH1A1
SCHEMBL24257808 0.81 PDK2 (0.39) PDK2MAPTKMT2AJAK2TYK2
SCHEMBL24257812 0.81 GRM5 (0.46) KDM5AATP4AATP4BGRM4
SCHEMBL24257536 0.80 GRM4 (0.44) KDM5AGRM4MAPTKDM4EALDH1A1
SCHEMBL24257687 0.79 CYP11B1 (0.42) ATP4AATP4BSQORMAPTHSD17B10
SCHEMBL30546888 0.79 CYP11B1 (0.42) ATP4AATP4BSQORMAPTHSD17B10
SCHEMBL24257777 0.78 MAPT (0.42) ATP4AATP4BSQORMAPTHSD17B10
SCHEMBL24257768 0.77 SQOR (0.42) SQORMAPTHSD17B10KDM4EALDH1A1
SCHEMBL24257578 0.77 CYP11B1 (0.47) SQORMAPTHSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 RET 2282/4885KDM5A 199/4885PDK2 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.